Personalized Cancer Vaccines Market
Personalized Cancer Vaccines Market Forecasts to 2034 - Global Analysis By Vaccine Type (Neoantigen-based Vaccines, Dendritic Cell Vaccines, mRNA-based Vaccines, Peptide-based Vaccines, DNA-based Vaccines, Tumor Cell Vaccines, and Other Vaccine Types), Delivery Method, Technology, Application, End User and By Geography
According to Stratistics MRC, the Global Personalized Cancer Vaccines Market is accounted for $1.4 billion in 2026 and is expected to reach $9.8 billion by 2034 growing at a CAGR of 27.4% during the forecast period. Personalized cancer vaccines refer to individualized immunotherapeutic constructs designed to prime the patient's immune system against tumor-specific antigens derived from genomic sequencing of their own malignant cells. They encompass neoantigen-based peptide formulations, mRNA delivery constructs, dendritic cell preparations, and DNA vaccine vectors. Manufactured through bioinformatics-driven neoantigen prediction and rapid manufacturing workflows, they are administered to melanoma, lung cancer, and other solid tumor patients, stimulating cytotoxic T-cell responses against patient-specific cancer mutations.
Market Dynamics:
Driver:
mRNA Technology Maturation
mRNA technology maturation is a transformative driver enabling scalable, rapid manufacturing of personalized neoantigen cancer vaccines that previously required months of production. Lipid nanoparticle delivery optimization validated through COVID-19 vaccine programs has directly transferred to oncology vaccine formulation, reducing manufacturing cycle times and improving payload stability. Major pharmaceutical entities are accelerating personalized mRNA cancer vaccine pipeline investments, generating late-stage clinical asset portfolios and substantiating commercial pathway feasibility.
Restraint:
Manufacturing Complexity and Cost
Manufacturing complexity and prohibitive per-patient production costs constrain personalized cancer vaccine accessibility, as each vaccine requires individual genomic sequencing, neoantigen prioritization, and bespoke peptide or mRNA synthesis within clinically meaningful timeframes. Sophisticated GMP biomanufacturing infrastructure and highly skilled personnel requirements elevate fixed costs substantially. These barriers disproportionately restrict access in healthcare systems with limited oncology drug budget flexibility, confining current commercial viability to premium market segments.
Opportunity:
Combination Immunotherapy Protocols
Combination immunotherapy protocols integrating personalized cancer vaccines with checkpoint inhibitors present a major opportunity, as clinical evidence increasingly demonstrates synergistic tumor response rates exceeding either modality alone. Oncology physicians and payers are showing growing acceptance of combination regimens where response durability justifies combined costs. Regulatory agencies are streamlining accelerated approval frameworks for combination oncology approaches, creating faster commercial pathways for personalized vaccine developers partnering with established checkpoint inhibitor manufacturers.
Threat:
Competitive Checkpoint Inhibitor Landscape
The entrenched competitive landscape of approved checkpoint inhibitors represents a significant threat to personalized cancer vaccine commercial adoption, as oncologists rely on well-characterized agents with established reimbursement and clinical guideline inclusion. Demonstrating superior efficacy versus existing standard of care in pivotal trials requires substantial investment and carries meaningful regulatory risk. Patient and physician resistance to experimental personalized approaches in lieu of proven therapies further constrains near-term uptake beyond clinical trial settings.
Covid-19 Impact:
COVID-19 profoundly accelerated personalized cancer vaccine development by validating mRNA delivery platforms and lipid nanoparticle manufacturing at scale. Pandemic-era partnerships between vaccine technology developers and oncology specialists created technology transfer opportunities that compressed development timelines. Post-pandemic, regulatory agencies introduced streamlined adaptive trial guidance applicable to personalized oncology therapeutics, structurally benefiting the pipeline.
The DNA-based vaccines segment is expected to be the largest during the forecast period
The DNA-based Vaccines segment is expected to account for the largest market share during the forecast period, due to their stability advantages over mRNA constructs, established manufacturing processes, and growing late-stage clinical pipeline across melanoma and lung cancer indications. DNA vaccines do not require ultra-cold storage, improving logistical feasibility for diverse clinical settings. Multiple Phase III trials evaluating personalized DNA vaccine platforms in combination with checkpoint inhibitors are generating positive interim data supporting commercial expectations.
The genomic sequencing segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Genomic Sequencing segment is predicted to witness the highest growth rate, driven by rapidly declining whole-exome sequencing costs and expanding clinical genomics infrastructure in major healthcare systems. Real-world genomic sequencing adoption for tumor profiling is accelerating as reimbursement coverage expands in the U.S. and Europe. The integration of next-generation sequencing workflows directly into hospital oncology pathways is generating the neoantigen data inputs essential for personalized vaccine manufacturing pipelines.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, due to advanced clinical trial infrastructure, leading biopharmaceutical investment in personalized oncology, and supportive regulatory environments including FDA breakthrough therapy and accelerated approval designations. The United States hosts the majority of late-stage personalized cancer vaccine clinical programs. High oncology drug expenditure and insurance coverage for genomic profiling create commercial conditions supporting early market penetration for approved personalized vaccine products.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding oncology patient populations, government investments in genomic medicine infrastructure, and growing clinical trial activity across China, Japan, and South Korea. National cancer control programs in major Asia Pacific economies are integrating genomic tumor profiling into standard diagnostic workflows. Accelerated regulatory approval pathways for innovative oncology biologics in Japan and China are facilitating faster market entry for personalized vaccine developers.
Key players in the market
Some of the key players in Personalized Cancer Vaccines Market include Moderna Inc., BioNTech SE, Gritstone bio, Inc., CureVac N.V., Roche Holding AG, Merck & Co., Inc., Pfizer Inc., AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Sanofi S.A., Genentech Inc., Immatics N.V., ISA Pharmaceuticals, Neon Therapeutics, Nouscom AG, Transgene SA, and Adaptimmune Therapeutics.
Key Developments:
In March 2026, Moderna Inc. announced expansion of its personalized cancer vaccine manufacturing capacity through a new U.S.-based GMP production facility partnership.
In February 2026, Roche Holding AG entered a co-development agreement to evaluate personalized neoantigen vaccine combination regimens with atezolizumab across multiple solid tumor types.
In January 2026, BioNTech SE reported positive Phase II data for its individualized neoantigen mRNA cancer vaccine combined with pembrolizumab in advanced melanoma patients.
In October 2025, Gritstone bio, Inc. initiated a Phase II clinical trial evaluating its GRANITE neoantigen cancer vaccine in combination with checkpoint immunotherapy for colorectal cancer.
Vaccine Types Covered:
• Neoantigen-based Vaccines
• Dendritic Cell Vaccines
• mRNA-based Vaccines
• Peptide-based Vaccines
• DNA-based Vaccines
• Tumor Cell Vaccines
• Other Vaccine Types
Delivery Methods Covered:
• Intravenous
• Subcutaneous
• Intradermal
• Intramuscular
• Nanoparticle Delivery
• Lipid Nanoparticles
Technologies Covered:
• Genomic Sequencing
• Next-Generation Sequencing (NGS)
• Bioinformatics Platforms
• Immunoinformatics
• AI-driven Vaccine Design
• Single-cell Analysis
Applications Covered:
• Melanoma
• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Hematological Malignancies
• Other Applications
End Users Covered:
• Hospitals
• Oncology Clinics
• Research Institutes
• Biotech Companies
• Pharma Companies
• Clinical Trial Centers
• Other End Users
Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
§ Saudi Arabia
§ United Arab Emirates
§ Qatar
§ Israel
§ Rest of Middle East
o Africa
§ South Africa
§ Egypt
§ Morocco
§ Rest of Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 Research Framework
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 Market Dynamics and Trend Analysis
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 Competitive and Strategic Assessment
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 Global Personalized Cancer Vaccines Market, By Vaccine Type
5.1 Neoantigen-based Vaccines
5.2 Dendritic Cell Vaccines
5.3 mRNA-based Vaccines
5.4 Peptide-based Vaccines
5.5 DNA-based Vaccines
5.6 Tumor Cell Vaccines
5.7 Other Vaccine Types
6 Global Personalized Cancer Vaccines Market, By Delivery Method
6.1 Intravenous
6.2 Subcutaneous
6.3 Intradermal
6.4 Intramuscular
6.5 Nanoparticle Delivery
6.6 Lipid Nanoparticles
7 Global Personalized Cancer Vaccines Market, By Technology
7.1 Genomic Sequencing
7.2 Next-Generation Sequencing (NGS)
7.3 Bioinformatics Platforms
7.4 Immunoinformatics
7.5 AI-driven Vaccine Design
7.6 Single-cell Analysis
8 Global Personalized Cancer Vaccines Market, By Application
8.1 Melanoma
8.2 Lung Cancer
8.3 Breast Cancer
8.4 Prostate Cancer
8.5 Colorectal Cancer
8.6 Hematological Malignancies
8.7 Other Applications
9 Global Personalized Cancer Vaccines Market, By End User
9.1 Hospitals
9.2 Oncology Clinics
9.3 Research Institutes
9.4 Biotech Companies
9.5 Pharma Companies
9.6 Clinical Trial Centers
9.7 Other End Users
10 Global Personalized Cancer Vaccines Market, By Geography
10.1 North America
10.1.1 United States
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 United Kingdom
10.2.2 Germany
10.2.3 France
10.2.4 Italy
10.2.5 Spain
10.2.6 Netherlands
10.2.7 Belgium
10.2.8 Sweden
10.2.9 Switzerland
10.2.10 Poland
10.2.11 Rest of Europe
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Australia
10.3.6 Indonesia
10.3.7 Thailand
10.3.8 Malaysia
10.3.9 Singapore
10.3.10 Vietnam
10.3.11 Rest of Asia Pacific
10.4 South America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Colombia
10.4.4 Chile
10.4.5 Peru
10.4.6 Rest of South America
10.5 Rest of the World (RoW)
10.5.1 Middle East
10.5.1.1 Saudi Arabia
10.5.1.2 United Arab Emirates
10.5.1.3 Qatar
10.5.1.4 Israel
10.5.1.5 Rest of Middle East
10.5.2 Africa
10.5.2.1 South Africa
10.5.2.2 Egypt
10.5.2.3 Morocco
10.5.2.4 Rest of Africa
11 Strategic Market Intelligence
11.1 Industry Value Network and Supply Chain Assessment
11.2 White-Space and Opportunity Mapping
11.3 Product Evolution and Market Life Cycle Analysis
11.4 Channel, Distributor, and Go-to-Market Assessment
12 Industry Developments and Strategic Initiatives
12.1 Mergers and Acquisitions
12.2 Partnerships, Alliances, and Joint Ventures
12.3 New Product Launches and Certifications
12.4 Capacity Expansion and Investments
12.5 Other Strategic Initiatives
13 Company Profiles
13.1 Moderna Inc.
13.2 BioNTech SE
13.3 Gritstone bio, Inc.
13.4 CureVac N.V.
13.5 Roche Holding AG
13.6 Merck & Co., Inc.
13.7 Pfizer Inc.
13.8 AstraZeneca plc
13.9 GlaxoSmithKline plc
13.10 Novartis AG
13.11 Sanofi S.A.
13.12 Genentech Inc.
13.13 Immatics N.V.
13.14 ISA Pharmaceuticals
13.15 Neon Therapeutics
13.16 Nouscom AG
13.17 Transgene SA
13.18 Adaptimmune Therapeutics
List of Tables
1 Global Personalized Cancer Vaccines Market Outlook, By Region (2023-2034)($MN)
2 Global Personalized Cancer Vaccines Market Outlook, By Vaccine Type (2023-2034)($MN)
3 Global Personalized Cancer Vaccines Market Outlook, By Neoantigen-based Vaccines (2023-2034)($MN)
4 Global Personalized Cancer Vaccines Market Outlook, By Dendritic Cell Vaccines (2023-2034)($MN)
5 Global Personalized Cancer Vaccines Market Outlook, By mRNA-based Vaccines (2023-2034)($MN)
6 Global Personalized Cancer Vaccines Market Outlook, By Peptide-based Vaccines (2023-2034)($MN)
7 Global Personalized Cancer Vaccines Market Outlook, By DNA-based Vaccines (2023-2034)($MN)
8 Global Personalized Cancer Vaccines Market Outlook, By Tumor Cell Vaccines (2023-2034)($MN)
9 Global Personalized Cancer Vaccines Market Outlook, By Other Vaccine Types (2023-2034)($MN)
10 Global Personalized Cancer Vaccines Market Outlook, By Delivery Method (2023-2034)($MN)
11 Global Personalized Cancer Vaccines Market Outlook, By Intravenous (2023-2034)($MN)
12 Global Personalized Cancer Vaccines Market Outlook, By Subcutaneous (2023-2034)($MN)
13 Global Personalized Cancer Vaccines Market Outlook, By Intradermal (2023-2034)($MN)
14 Global Personalized Cancer Vaccines Market Outlook, By Intramuscular (2023-2034)($MN)
15 Global Personalized Cancer Vaccines Market Outlook, By Nanoparticle Delivery (2023-2034)($MN)
16 Global Personalized Cancer Vaccines Market Outlook, By Lipid Nanoparticles (2023-2034)($MN)
17 Global Personalized Cancer Vaccines Market Outlook, By Technology (2023-2034)($MN)
18 Global Personalized Cancer Vaccines Market Outlook, By Genomic Sequencing (2023-2034)($MN)
19 Global Personalized Cancer Vaccines Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034)($MN)
20 Global Personalized Cancer Vaccines Market Outlook, By Bioinformatics Platforms (2023-2034)($MN)
21 Global Personalized Cancer Vaccines Market Outlook, By Immunoinformatics (2023-2034)($MN)
22 Global Personalized Cancer Vaccines Market Outlook, By AI-driven Vaccine Design (2023-2034)($MN)
23 Global Personalized Cancer Vaccines Market Outlook, By Single-cell Analysis (2023-2034)($MN)
24 Global Personalized Cancer Vaccines Market Outlook, By Application (2023-2034)($MN)
25 Global Personalized Cancer Vaccines Market Outlook, By Melanoma (2023-2034)($MN)
26 Global Personalized Cancer Vaccines Market Outlook, By Lung Cancer (2023-2034)($MN)
27 Global Personalized Cancer Vaccines Market Outlook, By Breast Cancer (2023-2034)($MN)
28 Global Personalized Cancer Vaccines Market Outlook, By Prostate Cancer (2023-2034)($MN)
29 Global Personalized Cancer Vaccines Market Outlook, By Colorectal Cancer (2023-2034)($MN)
30 Global Personalized Cancer Vaccines Market Outlook, By Hematological Malignancies (2023-2034)($MN)
31 Global Personalized Cancer Vaccines Market Outlook, By Other Applications (2023-2034)($MN)
32 Global Personalized Cancer Vaccines Market Outlook, By End User (2023-2034)($MN)
33 Global Personalized Cancer Vaccines Market Outlook, By Hospitals (2023-2034)($MN)
34 Global Personalized Cancer Vaccines Market Outlook, By Oncology Clinics (2023-2034)($MN)
35 Global Personalized Cancer Vaccines Market Outlook, By Research Institutes (2023-2034)($MN)
36 Global Personalized Cancer Vaccines Market Outlook, By Biotech Companies (2023-2034)($MN)
37 Global Personalized Cancer Vaccines Market Outlook, By Pharma Companies (2023-2034)($MN)
38 Global Personalized Cancer Vaccines Market Outlook, By Clinical Trial Centers (2023-2034)($MN)
39 Global Personalized Cancer Vaccines Market Outlook, By Other End Users (2023-2034)($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
